Inactivation of platelet PDE2 by an Affinity Label: 8-[(4-Bromo-2,3-Dioxobutyl)Thio]cAMP

Thrombosis Research

Volumn 98, Issue 5, 2000, Pages 395-401

  Mseeh, Faika ^a   Colman, Roberta F ^b   Colman, Robert W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

Author keywords

Affinity label; cAMP phosphodiesterase; cGMP; Platelets

Indexed keywords

8 [(4 BROMO 2,3 DIOXOBUTYL)THIO] CYCLIC AMP; CYCLIC AMP; CYCLIC AMP DERIVATIVE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP; UNCLASSIFIED DRUG;

AFFINITY LABELING; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

AFFINITY LABELS; BINDING SITES; BLOOD PLATELETS; CYCLIC AMP; CYCLIC GMP; HUMANS; ISOENZYMES; KINETICS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; THIONUCLEOTIDES;

EID: 0034212271     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00195-X     Document Type: Article

References (21)

1. Salzman E.W., Weisenberger H. Role of cyclic AMP in platelet function. Adv Cyclic Nucleotide Res. 1:1972;231-247. [Review].
2. Simonds W.F., Goldsmith P.K., Codina J., Unson C.G., Spiegel A.M. Gi2 mediates α2-adrenergic inhibition of adenylyl cylcase in platelet membranes. In situ identification with Gα C-terminal antibodies Proc Natl Acad Sci USA. 86:1989;7809-7813.
3. Alvarez R., Taylor A., Fazzari J.J., Jacobs J.R. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins. Mol Pharmacol. 20:1981;302-309.
4. Seiler S., Gillespie E., Arnold A.J., Brassard C.L., Meanwell N.A., Fleming J.S. Imidazoquinoline derivatives. Potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets Thromb Res. 62:1991;31-42.
5. Siegl A.M., Daly J.W., Smith J.B. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol. 21:1982;680-687.
6. Tani T., Sakurai K., Kimura Y., Ishikawa T., Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res. 25:1992;215-227.
7. Juilfs D.M., Soderling S., Burns F., Beavo J.A. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol. 135:1999;67-104.
8. Charbonneau H. Structure-function relationships among cyclic nucleotide phosphodiesterases. Beavo J., Houslay M.D. Cyclic Nucleotide Phosphodiesterases. Structure, Regulation and Drug Action:1990;267-296 John Wiley and Sons, New York.
9. Hidaka H., Asano T. Human blood platelet 3′:5′-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta. 429:1976;485-497.
10. Asano T., Ochiai Y., Hidaka H. Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors. Mol Pharmacol. 13:1977;400-406.
11. Hidaka H., Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase. Basic and potential clinical applications Adv Cyclic Nucleotide Protein Phosphorylation Res. 16:1984;245-259.
12. Grant P.G., Mannarino A.F., Colman R.W. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets. Thromb Res. 59:1990;105-119.
13. Kambayashi J., Watase M., Kawasaki T., Shiba E., Sakon M., Mori T., Isaka Y., Kimura K., Kamada T. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery. Adv Second Messenger Phosphoprotein Res. 25:1992;383-393.
14. Grant P.G., DeCamp D.L., Bailey J.M., Colman R.W., Colman R.F. Three new potential cAMP affinity labels. Inactivation of human platelet low Km cAMP phosphodiesterase by 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3′,5′-cyclic monophosphate. Biochemistry. 29:1990;887-894.
15. Omburo G.A., Torphy T.J., Scott G., Jacobitz S., Colman R.F., Colman R.W. Inactivation of recombinant monocyte cAMP-specific phosphodiesterase by cAMP analog, 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3′,5′-cyclic monophosphate. Blood. 89:1997;1019-1026.
16. Sinha A.K., Shattil S.J., Colman R.W. Cyclic AMP metabolism in cholesterol-rich platelets. J Biol Chem. 252:1977;3310-3314.
17. Ashida S., Sakuma K. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. Adv Second Messenger Phosphoprotein Res. 25:1992;229-239.
18. Grant P.G., Colman R.W. Purification of cAMP phosphodiesterase from platelets. Methods Enzymol. 159:1988;772-777.
19. Radomski M.W., Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost. 70:1993;36-41.
20. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium. Interactions between prostacyclin and nitric oxide Br J Pharmacol. 92:1987;639-646.
21. Maurice D.H., Haslam R.J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase. Inhibition of cyclic AMP breakdown by cyclic GMP Mol Pharmacol. 37:1990;671-681.